---
title: "Alkermes rises on Q4 sales beat"
date: "2025-02-12 23:54:23"
summary: "** Shares of drugmaker Alkermes rise 6.38% to $34 ** Co posts Q4 sales of $430 million, beating analysts' estimate of $379 million - LSEG ** Sees 2025 revenue between $1.3 billion and $1.4 billion vs est $1.4 billion ** Expects mid-stage study data of neurological disorder drug in H2..."
categories:
  - "Reuters"
lang:
  - "en"
translations:
  - "en"
tags:
  - "Reuters"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

\*\* Shares of drugmaker Alkermes rise 6.38% to $34

\*\* Co [posts](https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250212:nPre6lzzba&default-theme=true) Q4 sales of $430 million, beating analysts' estimate of $379 million - LSEG

\*\* Sees 2025 revenue between $1.3 billion and $1.4 billion vs est $1.4 billion

\*\* Expects mid-stage study data of neurological disorder drug in H2Â 2025

\*\* Plans to begin early-stage study of drugs to treat sleep disorders

\*\* In the last 12 months, ALKS rose 7.6%

[Reuters](https://www.tradingview.com/news/reuters.com,2025:newsml_L4N3P31AR:0-alkermes-rises-on-q4-sales-beat/)
